tbuckley/cabot-search huggingface dataset:
FRI0421 Development of Clinessdai Score (Clinical Eular Sjögren's Syndrome Disease Activity Index) Without Biological Domain: A Tool For Biological Studies
Authors: R. Seror, G. Baron, C. Vitali, S. Bowman, J.-E. Gottenberg, A. Tzioufas, E. Theander, H. Bootsma, T. Doerner, M. Ramos-Casals, X. Mariette, P. Ravaud
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> ESSDAI is a validated activity index in primary Sjögren9s syndrome more and more used in clinical trials but also for finding biomarkers associated with activity of the disease. In this context, the presence of the biological domain in the ESSDAI score may induce circular reasoning and colinearity of data. <h3>Objectives</h3> To develop the ClinESSDAI, derived from the ESSDAI score after deleting biological domain, and to validate if by comparison with the original ESSDAI. <h3>Methods</h3> The 702 fictive vignettes created using data from 96 real cases of pSS for the study of development ESSDAI were used. As for the development of the original score, the assessment by the 39 experts who participated to the development study of disease activity using a scale ranging from 0-10 was used as the “gold standard” for weighting domains in the robust regression model. The explanatory variables included all domain of ESSDAI except the biological domain. The ClinESSDAI was compared to original ESSDAI to assess if it could be a surrogate of the original score by assessing its reproducibility using ESSDAI as gold standard. The validity of ClinESSDAI (including construct validity, reliability and sensitivity to change) was then assessed and compared to that of ESSDAI. Validation populations included the 96 real cases and the 395 patients of the EULAR cohort. <h3>Results</h3> In the multivariate model, each of the 11 areas was significantly associated with disease activity. The weight of the domains was slightly different from the fields of ESSDAI (table). The ClinESSDAI was an excellent surrogate of the original ESSDAI, since the ICC between ESSDAI and ClinESSDAI were0.98 [0.97; 0.98] for fictive vignettes, 0.99 [0.98; 0.99] for the real case and0.90 [0.87; 0.92] in the EULAR cohort. Psychometric properties of the ClinESSDAI (construct validity, reliability and sensitivity to change) were very close to that of ESSDAI. <h3>Conclusions</h3> Declination of the ESSDAI score without biological domain appears valid and very close to the original score. In this score, weights of some domains changed. This score will allow an evaluation of disease activity that is independent ofB-cell biomarkers, which will be useful in biological studies to avoid circular reasoning and colinearity of data. In addition, it may be helpful in clinical practice to assess disease activity when immunological tests have not been carried out. <h3>Disclosure of Interest</h3> None declared
Pyonephrosis in a duplex kidney: diagnosis facilitated by skeletal scintigraphy.
Authors: LEONARD CONNOLLY, SUSAN CONNOLLY, LAURA DRUBACH, S. TED TREVES
Journal: Clinical Nuclear Medicine (2001)

CONNOLLY, LEONARD P. M.D.; CONNOLLY, SUSAN A. M.D.; DRUBACH, LAURA A. M.D.; TED TREVES, S. M.D. Author Information
Hypertension, the Swedish Patient Register, and Selection Bias
Authors: Mattias Brunström
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
ECT in the treatment of mania: a controlled study
Authors: M S McCabe
Journal: American Journal of Psychiatry (1976)

In a chart review study of manic patients, the author found that ECT remarkably improved outcome variables of condition at discharge, duration of hospitalization, and social recovery in comparison with an untreated matched control group. More conclusive evidence would depend on a prospective trial with random assignment of manic patients to ECT, lithium carbonate, and major tranquilizers and blind evaluation of outcome.
PWE-141 Alfa pump for the treatment of refractory ascites: a “real world” experience from the uk
Authors: S Nair, E Robinson, S Fiona, S Macdonald, H Mergental, D Talbot, D Tripathi, B Griffiths, R Jalan, S Mcpherson
Journal: Gut (2015)

<h3>Introduction</h3> Up to 10% of cirrhotic patients with ascites become refractory to diuretic therapy requiring either large volume paracenteses (LVP), transcutaneous intrahepatic portosystemic shunt (TIPSS) or liver transplantation (LT). In patients where TIPSS or LT is contraindicated, repeated LVP is the only option. LVP is an uncomfortable procedure requiring hospital visits and has risk of complications. The ALFA pump is a surgically implanted automated low flow pump system that transports fluid from the peritoneal cavity to the bladder and is an alternative treatment option for patients with refractory ascites. Our aim was to evaluate the early “real world” experience of the ALFA pump for the treatment of refractory ascites from centres in the UK. <h3>Method</h3> Retrospective case note review of the outcomes of patients who had an ALFA pump implanted for refractory ascites outside trials at 4 NHS hospitals since Sept 2013. <h3>Results</h3> ALFA pumps were implanted in 9 patients (6 male, 3 female; median age 74, range 41–81) at four centres (4 NCL, 2 UCL, 2 CAM, 1 QEHB). 7 patients had ascites related to cirrhosis (4 Child-Pugh B, 3 Child-Pugh C), 1 due to congestive cardiac failure and 1 with portal hypertension due to arterio-venous malformation. Prior to insertion of the ALFA pump the median frequency of paracenteses was every 10 days (range 7 – 20) and the median volume of ascites drained was 9 litres (range 8 to 12). ALFA pumps were successfully implanted in all patients. Requirement for paracenteses was substantially reduced post ALFA pump implantation with 7 patients no longer requiring any paracenteses. In one patient the pump blocked after 3 weeks and required reimplantation with a second pump that also blocked and the patient has returned to LVP. In another patient the pump blocked after 8 months and a second ALFA pump was successfully implanted. All 9 patients had ALFA pump related complications including 4 post-operative seromas, 3 bladder catheter migrations/occlusions, 5 site related infections, 6 acute kidney injury/electrolyte disturbance and 1 urinary incontinence. 5 of the 9 patients were alive with a functioning pump 6 months after implantation. <h3>Conclusion</h3> The ALFA pump offers an alternative option for patients who have refractory ascites in whom TIPSS and LT are contraindicated. ALFA pump implantation substantially reduces the need for paracenteses in a cohort of patients who had previously required a significant number of LVP. ALFA pump related complications were frequent suggesting the need for careful patient selection in this high risk group. Outcomes of a randomised controlled trial are eagerly awaited. <h3>Disclosure of interest</h3> None Declared.
Nitrate from Drinking Water and Diet and Bladder Cancer Among Postmenopausal Women in Iowa
Authors: Rena R. Jones, Peter J. Weyer, Curt T. DellaValle, Maki Inoue-Choi, Kristin E. Anderson, Kenneth P. Cantor, Stuart Krasner, Kim Robien, Laura E. Beane Freeman, Debra T. Silverman, Mary H. Ward
Journal: Environmental Health Perspectives (2016)

Nitrate is a drinking water contaminant arising from agricultural sources, and it is a precursor in the endogenous formation of N-nitroso compounds (NOC), which are possible bladder carcinogens.
Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care
Authors: Deena R. Levine, Liza-Marie Johnson, Angela Snyder, Robert K. Wiser, Deborah Gibson, Javier R. Kane, Justin N. Baker
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: The demonstrated benefit of integrating palliative care (PC) into cancer treatment has triggered an increased need for PC services. The trajectory of integrating PC in comprehensive cancer centers, particularly pediatric centers, is unknown. We describe our 8-year experience of initiating and establishing PC with the Quality of Life Service (QoLS) at St. Jude Children's Research Hospital. Methods: We retrospectively reviewed records of patients seen by the QoLS (n=615) from March 2007 to December 2014. Variables analyzed for each year, using descriptive statistics, included diagnostic groups, QoLS encounters, goals of care, duration of survival, and location of death. Results: Total QoLS patient encounters increased from 58 (2007) to 1,297 (2014), new consults increased from 17 (2007) to 115 (2014), and mean encounters per patient increased from 5.06 (2007) to 16.11 (2014). Goal of care at initial consultation shifted from primarily comfort to an increasing goal of cure. The median number of days from initial consult to death increased from 52 days (2008) to 223 days (2014). A trend toward increased outpatient location of death was noted with 42% outpatient deaths in 2007, increasing to a majority in each subsequent year (range, 51%–74%). Hospital-wide, patients receiving PC services before death increased from approximately 50% to nearly 100%. Conclusions: Since its inception, the QoLS experienced a dramatic increase in referrals and encounters per patient, increased use by all clinical services, a trend toward earlier consultation and longer term follow-up, increasing outpatient location of death, and near-universal PC involvement at the end-of-life. The successful integration of PC in a comprehensive cancer center, and the resulting potential for improved care provision over time, can serve as a model for other programs on a broad scale.
Effect of naloxone on the neuropsychiatric symptoms of a woman with partial adrenal 21-hydroxylase deficiency
Authors: I Blum, A Elizur, A Segal, M Ochshorn, R Simantov
Journal: American Journal of Psychiatry (1983)

A woman with a schizophreniform syndrome, drug-induced dyskinetic movements, and partial adrenocortical 21-hydroxylase deficiency was given short-term treatment with naloxone, which ameliorated the psychiatric symptoms and eliminated the dyskinetic movements.
Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Ph1-positive acute lymphoblastic leukemia with myeloid surface markers.
Authors: Tsuchiya H, Adachi N, Asou N, Takatsuki K, Matsuda I, Kawano F, Murakami T, Mizutani S, Watanabe M
Journal: Blood (1991)
AB0752 Treatment Impact on Sleep Disorders in Axial Spondyloarthritis Patients:
Authors: I. Mahmoud, R. Dhahri, O. Saidane, H. Sahli, I. Chrif, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Treatment innovations have changed prfoundly spondyloarthritis prognosis. <h3>Objectives</h3> To assess treatment impact on sleep quality in Axial Spondyloarthritis (AS) patients. <h3>Methods</h3> A cross sectional case-control study was conducted between August 2012 and August 2013 in the department of Rheumatology of Charles Nicolle Hospital. Only patients with Axial Spondyloarthritis according to the 2009 Eular criteria were included. The 100 age- and sex-matched healthy controls were included in this case-control study. Sleep during the month preceding the evaluation was examined by MOS-SS. <h3>Results</h3> One hundred patients with AS and 100 control group patients age and sex matched participated in this study. Patients were divided into 71 men and 29 women. Their average age is 41.72 years [16-74]. Seventy four percent of patients were on NSAIDs, 56% were under DMARDs and 12% on TNF alpha blockers. Controls had fewer sleep problems in all MOSS-SS9s fields, compared to AS regardless of the treatment they were receiving, except in the field of snoring, where they were comparable to the patients on biologic DMARDs and significantly lower than NSAID/DMARDS groups. TNF blockers therapy did not show superiority in improving different sleep scores except for one MOSS-SS9s domain (Snoring) (table). <h3>Conclusions</h3> The impact of treatment was modest. Surprisingly, the TNF blockers therapy did not show superiority in improving different sleep scores except for one MOSS-SS9s domain (Snoring). <h3>Disclosure of Interest</h3> None declared
An evaluation of detoxification as an initial step in the treatment of heroin addiction
Authors: A Sheffet, M Quinones, M A Lavenhar, K Doyle, H Prager
Journal: American Journal of Psychiatry (1976)

Of 802 voluntary patients admitted to the detoxification unit of a comprehensive treatment system, 69% completed detoxification but only 9.6% of thest patients sought long-term treatment. The demographic profile of detoxification patients differed somewhat from that of patients in long-term treatment. The authors suggest that new approaches, including legal pressure, are needed to induce detoxification patients to accept prolonged therapy.
ECT and Parkinson's disease revisited: a "naturalistic" study
Authors: R Douyon, M Serby, B Klutchko, J Rotrosen
Journal: American Journal of Psychiatry (1989)

In an open study, seven patients with Parkinson's disease received ECT for major depression. Both the motor dysfunction and the mood impairment of these patients improved following an average of seven ECT sessions. Significant improvement in motor function occurred after only two treatments. All aspects of Parkinson's disease improved significantly after ECT. Older patients showed greater improvement in motor function. The authors conclude that the therapeutic utility of ECT in depressed and nondepressed patients with Parkinson's disease should be further evaluated.
Obstacles in the treatment of dying patients
Authors: P Levinson
Journal: American Journal of Psychiatry (1975)

Theory and practice in the management of the dying patient have moved forward in the past two decades. However, the author believes the benefits of this progress have not reached a large segment of the population of dying patients--those individuals who have a higher level of psychopathology or are from a lower socioeconomic group. Obstacles in the treatment of such patients are described and illustrated by case histories; the author makes specific recommendations related to the care of these more difficult cases.
Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism
Authors: Aiman S. Saab, Iva D. Tzvetavona, Andrea Trevisiol, Selva Baltan, Payam Dibaj, Kathrin Kusch, Wiebke Möbius, Bianka Goetze, Hannah M. Jahn, Wenhui Huang, Heinz Steffens, Eike D. Schomburg, Alberto Pérez-Samartín, Fernando Pérez-Cerdá, Davood Bakhtiari, Carlos Matute, Siegrid Löwel, Christian Griesinger, Johannes Hirrlinger, Frank Kirchhoff, Klaus-Armin Nave
Journal: Neuron (2016)
A combination of the clip-with-line method and the tunnel technique during esophageal endoscopic submucosal dissection: a technical solution?
Authors: Jérémie Jacques, Sophie Geyl, Paul Carrier, Tessa Tabouret, Veronique Loustaud-Ratti, Denis Sautereau, Romain Legros
Journal: Endoscopy (2015)

A 76-year-old woman was referred to our endoscopy unit for endoscopic submucosal dissection (ESD) of a 3-cm-diameter nodule exhibiting high grade dysplasia and complicating a large Barrett's esophagus. A classic tunnel was created beneath the lesion ([Fig. 1]) with a HybridKnife Type T (ERBE Electromedizin, Tübingen, Germany). After incision of the mucosa on both sides of the tumor, the scope was withdrawn. A Resolution Clip (Boston Scientific, Natick, Massachusetts, USA) was inserted into the operative channel of the endoscope and attached to a 250-cm line made of nonabsorbable suture wire (Peters Surgical, Paris, France) bent in a U-shape. The scope was reinserted with the line in parallel, and the clip with the attached line was placed at the proximal side of the tunnel ([Fig. 2] and [Fig. 3]). Constant countertraction, applied by grasping the external part of the linewith a plastic 11 g Kocher forceps (Nessicare dressing kit, LCH Medical Products, Paris, France), facilitated excellent exposure of the remaining submucosal layers ([Fig. 4] and [Fig. 5]) on both sides, greatly aiding dissection after tunneling ([Fig. 6], [Video 1]).
SAT0245 In VIVO Evidence of IL-17/IL-23 Axis Activation in Ankylosing Spondylitis Patients with Long-Term TNF Blockade: The Missing Therapy Target?
Authors: F.M. Milanez, C.G. Saad, V.T. Viana, J.C. Moraes, G.V. Perico, C.A. Silva, C.R. Goncalves, E. Bonfa
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In spite of recent evidences regarding the relevance of IL-23/IL-17 axis in Ankylosing Spondylitis (AS) pathogenesis, there are no data on the long-term effect of anti-TNF therapy in this pathway and their possible correlation with treatment, clinical, laboratory and radiographic parameters. <h3>Objectives</h3> Investigate the influence of TNF-blockage in IL-23/IL-17 axis of AS patients. <h3>Methods</h3> Eighty-six AS patients, 47 with refractory active disease (BASDAI≥4) referred to anti-TNF therapy and 39 AS patients with BASDAI&lt;4 (AS control group) were included. The AS active group was evaluated at baseline, 12 months and 24 months after TNF blockage and compared at baseline to the AS control group and to 47 healthy age- and gender-matched controls. Plasma levels of IL-17A, IL-22, TNFα, IL-23, PGE2 were measured. Radiographic severity and progression was assessed by mSASSS. <h3>Results</h3> At baseline, active AS patients presented higher IL-23 and PGE2 plasma levels compared to AS control group (p&lt;0.001 and p=0.008) and to healthy controls (p&lt;0.001 and p=0.02). After 24 months of TNF blockage, IL-23 and PGE2 remained elevated with higher levels compared to healthy group (p&lt;0.001 and p=0.03) in spite of significant improvement in all clinical (ASDAS-CRP, BASFI, BASMI and ASQol, p&lt;0.001) and inflammatory parameters (C-reactive protein and ESR, p&lt;0.001). Further analysis of 27 anti-TNF treated patients that achieved good-response (ASDAS-CRP&lt;2.1 with Δ≥1.1) at 24 months revealed that their IL-23 plasma levels were higher than healthy controls (p&lt;0.001) and higher than 21 AS control group with similar disease activity (ASDAS-CRP&lt;2.1),(p=0.01). No predictor for anti-TNF response or to radiographic progression was identified. In AS active group (n=47), there was a strong correlation between IL-23 and IL-17A at baseline (r=0.64, p&lt;0.001), 12 months (r=0.47, p=0.001) and 24 months (r=0.61, p&lt;0.001). IL-23 was also correlated with PGE2 at 12 months (r=0.45, p=0.001) and 24 months (r=0.33, p&lt;0.05). No correlation was observed between NSAID, cytokines levels and radiographic progression (p&gt;0.05). <h3>Conclusions</h3> This study provides novel data demonstrating that IL-23/IL-17 axis is not influenced by TNF blockage in AS patients despite clinical and inflammation improvement and NSAID intake. In this context, IL-23/IL-17 blockage emerges as potential additional target in AS patients. <h3>References</h3> Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014;57:28-37. Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 2014;26:361-370. <h3>Disclosure of Interest</h3> None declared
SIR JOHN PRINGLE (1707-1782)— MILITARY PHYSICIAN AND HYGIENIST
Authors: D HAMILTON
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0680 Autoantibodies in Idiopathic Inflammatory Myopathies
Authors: A. Faten, L. Laadhar, I. Ben Ghorbel, M. Kallel-Sellami, H. Houman
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Idiopathic inflammatory myopathies (IIM) are autoimmune diseases characterized by inflammation of skeletal muscle tissue. There are several clinical entities: polymyositis (PM), dermatomyositis (DM), the inclusions body myositis (MI), the anti-synthetase syndrome (ASS), etc. <h3>Objectives</h3> The objective of this study was to determine the prevalence of a wide range of autoantibodies in patients with IIM. <h3>Methods</h3> We identified all patients with IIM addressed by the Internal Medicine Department, between January 2006 and February 2014 for immunological tests. The myositic-specific antibodies MSA (anti-Mi-2, anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-SRP) and the myositic-associated antibodies MAA (anti-Ku, ani-PM-Scl75, anti-PM-Scl100, anti-Ro-52) were detected by immunodot (Euroimmun®). Other antibodies were also investigated: anti-nuclear antibodies (ANA) by indirect immunofluorescence on Hep2 cells (Biorad®), anti-soluble nuclear antigens antibodies (anti-ENA), anti-DNA antibodies, anti-thyroperoxydases (ATPO), anti-thyroglobulins (Athy) and rheumatoid factors (RF) by Elisa (Human®). <h3>Results</h3> We identified 54 patients including 10 with PM, 36 with DM and 8 with ASS. It was 41 women and 13 men with an average age of 44 years [range: 12-74 years]. More than half (28/54) had an associated autoimmune disease. MSA were detected in 38 patients (70%). Among these antibodies, anti-Mi-2, Jo-1, PL-7, PL-12 and SRP were positive in 20%, 17%, 2%, 4% and 30% of cases, respectively. No patient had anti-EJ or anti-OJ. Among the MAA, anti-Ku, anti-PM-Scl75, anti-PM-Scl100 and anti-Ro-52 were positive in 20%, 13%, 20% and 44% of cases, respectively. ANA were positive in 87% of cases, of which only 28% were at a strong title ≥1/800. Anti-ENA, anti-DNA, ATPO, Athy and RF were positive in 33%, 7%, 41%, 15%, and 37% of cases, respectively. Three patients (6%) had no antibodies. <h3>Conclusions</h3> We report a high prevalence of MSA in Tunisian patients with IIM, especially anti-SRP. Furthermore, the presence of several MAA might be related to associated autoimmune diseases but can also reflect a particular autoimmune profile in these patients. <h3>Disclosure of Interest</h3> None declared